Corcept Therap Drug Patent Portfolio
Corcept Therap owns 1 orange book drug protected by 18 US patents Given below is the list of Corcept Therap's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10231983 | Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients | 22 Aug, 2038 | Active |
| US10314850 | Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients | 22 Aug, 2038 | Active |
| US10780097 | Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients | 22 Aug, 2038 | Active |
| US10195214 | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors | 19 Jun, 2037 | Active |
| US10842800 | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors | 19 Jun, 2037 | Active |
| US11969435 | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors | 19 Jun, 2037 | Active |
| US12097210 | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors | 19 Jun, 2037 | Active |
| US10151763 | Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome | 18 Jan, 2037 | Active |
| US9829495 | Method for differentially diagnosing ACTH-dependent Cushing's syndrome | 15 Aug, 2036 | Active |
| US10006924 | Method for differentially diagnosing ACTH-dependent cushing's syndrome | 12 Aug, 2036 | Active |
| US10495650 | Method for differentially diagnosing ACTH-dependent Cushing's syndrome | 12 Aug, 2036 | Active |
| US10166242 | Optimizing mifepristone levels for Cushing's patients | 20 Apr, 2036 | Active |
| US10166243 | Optimizing mifepristone levels for cushing'S patients | 20 Apr, 2036 | Active |
| US10660904 | Optimizing mifepristone levels for cushing's patients | 20 Apr, 2036 | Active |
| US9943526 | Optimizing mifepristone levels for cushing's patients | 20 Apr, 2036 | Active |
| US10500216 | Optimizing mifepristone absorption | 05 Mar, 2033 | Active |
| US10842801 | Optimizing mifepristone absorption | 15 Nov, 2032 | Active |
| US8921348 | Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists | 27 Aug, 2028 | Active |
Latest Legal Activities on Corcept Therap's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Corcept Therap.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 08 May, 2024 | US10842800 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 08 May, 2024 | US10842801 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 06 Mar, 2024 | US10780097 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 08 Nov, 2023 | US10660904 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 24 May, 2023 | US10500216 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 17 May, 2023 | US10495650 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 23 Nov, 2022 | US10314850 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 07 Sep, 2022 | US10231983 |
| Review Certificate Mailed | 03 Aug, 2022 | US10195214 |
| AIA Appeal returned from Federal Circuit | 25 Jul, 2022 | US10195214 |
| Review Certificate | 25 Jul, 2022 | US10195214 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 20 Jul, 2022 | US10195214 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 15 Jun, 2022 | US10166242 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 15 Jun, 2022 | US10166243 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 25 May, 2022 | US10151763 |
Corcept Therap's Drug Patent Litigations
Corcept Therap's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 02, 2018, against patent number US8921348. The petitioner Neptune Generics LLC, challenged the validity of this patent, with Corcept Therapeutics Inc. as the respondent. Click below to track the latest information on how companies are challenging Corcept Therap's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US10195214 | May, 2019 |
FWD Entered
(18 Nov, 2020)
| Corcept Therapeutics, Inc. | Teva Pharmaceuticals USA, Inc. |
| US8921348 | August, 2018 |
FWD Entered
(10 Feb, 2020)
| Corcept Therapeutics Inc. | Neptune Generics LLC |
Corcept Therap's Family Patents
Corcept Therap drugs have patent protection in a total of 12 countries. It has a significant patent presence in the US with 59.4% of its patents being US patents. Click
below to unlock the full patent family tree.
Corcept Therap Drug List
Given below is the complete list of Corcept Therap's drugs and the patents protecting them.
1. Korlym
Korlym is protected by 18 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10231983 | Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
22 Aug, 2038
(13 years from now)
| Active |
| US10314850 | Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
22 Aug, 2038
(13 years from now)
| Active |
| US10780097 | Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
22 Aug, 2038
(13 years from now)
| Active |
| US10195214 | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
19 Jun, 2037
(12 years from now)
| Active |
| US10842800 | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
19 Jun, 2037
(12 years from now)
| Active |
| US11969435 | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
19 Jun, 2037
(12 years from now)
| Active |
| US12097210 | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
19 Jun, 2037
(12 years from now)
| Active |
| US10151763 | Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome |
18 Jan, 2037
(12 years from now)
| Active |
| US9829495 | Method for differentially diagnosing ACTH-dependent Cushing's syndrome |
15 Aug, 2036
(11 years from now)
| Active |
| US10006924 | Method for differentially diagnosing ACTH-dependent cushing's syndrome |
12 Aug, 2036
(11 years from now)
| Active |
| US10495650 | Method for differentially diagnosing ACTH-dependent Cushing's syndrome |
12 Aug, 2036
(11 years from now)
| Active |
| US10166242 | Optimizing mifepristone levels for Cushing's patients |
20 Apr, 2036
(11 years from now)
| Active |
| US10166243 | Optimizing mifepristone levels for cushing'S patients |
20 Apr, 2036
(11 years from now)
| Active |
| US10660904 | Optimizing mifepristone levels for cushing's patients |
20 Apr, 2036
(11 years from now)
| Active |
| US9943526 | Optimizing mifepristone levels for cushing's patients |
20 Apr, 2036
(11 years from now)
| Active |
| US10500216 | Optimizing mifepristone absorption |
05 Mar, 2033
(8 years from now)
| Active |
| US10842801 | Optimizing mifepristone absorption |
15 Nov, 2032
(7 years from now)
| Active |
| US8921348 | Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists |
27 Aug, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Korlym's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List